Shares in Senseonics (NYSE:SENS) fell today after the medical device maker missed EPS expectations but met sales estimates on Wall Street with its third quarter financial results. The Germantown, Md.-based company posted a net loss of -$31.9 million on sales of $5.2 million for the 3 months ended Sept. 30. Quarterly net losses were up 83% on sales […]
Senseonics wins another FDA approval for its implantable CGM
Senseonics (NYSE:SENS) said this week that it won another FDA approval for its implantable continuous glucose monitoring system, giving nurse practitioners and physicians assistants the ability to implant and remove the Eversense device. When the product was first approved by the FDA in June, only trained physicians were allowed to conduct the sensor insertion and removal procedures. Get […]
Senseonics wins coverage from Aetna for Eversense glucose monitor
Senseonics (NYSE:SENS) said this week that won coverage from health plan provider Aetna for its Eversense continuous glucose monitoring system. Aetna provides coverage for roughly 22 million people in the U.S., according to Senseonics, making it the third largest commercial health plan provider in the country. Get the full story at our sister site, Drug Delivery […]
Senseonics launches Eversense implantable glucose monitor
Senseonics (NYSE:SENS) said today that its Eversense continuous glucose monitoring system is available at clinics across the U.S. The Germantown, Md.-based company also touted that it won coverage for its CGM with Horizon Blue Cross Blue Shield of New Jersey and Horizon Healthcare of New Jersey. Get the full story at our sister site, Drug Delivery Business […]
Senseonics inks diabetes management deal with Glooko
Senseonics (NYSE:SENS) said today that it inked a global deal to integrate its Eversense continuous glucose monitoring system with Glooko‘s diabetes data management tech. Users will be able to sync data from their Eversense CGM directly into Glooko’s platform and view historical glucose trends, as well as receive real-time readings from their Eversense mobile app, according to […]
Senseonics closes $150m public offering
Senseonics (NYSE:SENS) said today that it closed an underwritten public offering of its common stock, reeling in $149.5 million in total proceeds. The Germantown, Md.-based company plans to use its newly-acquired funds to support the commercialization of its implantable continuous glucose monitoring system, Eversense. Get the full story at our sister site, Drug Delivery Business News.
Senseonics prices $130m public offering
On the heels of an FDA approval for its implantable continuous glucose monitoring tech, Senseonics‘ (NYSE:SENS) today priced a $130 million underwritten public offering of common stock. The offering, which is slated to close on June 28, also includes a 30-day option for underwriters to buy additional shares of common stock worth up to $19.5 million. Get […]
FDA approves Senseonics’ implantable continuous glucose monitor
The FDA this week approved Senseonics‘ (NYSE:SENS) Eversense continuous glucose monitor for use in people ages 18 and older with diabetes. The device is the first CGM system to feature an implantable sensor that can be worn for up to 90 days. Get the full story at our sister site, Drug Delivery Business News.
Beta Bionics taps Senseonics’ implantable glucose monitor for artificial pancreas
Senseonics‘ (NYSE:SENS) said today that it inked a deal to integrate glucose data from its Eversense continuous glucose monitoring system into Beta Bionics‘ investigational iLet bionic pancreas. According to the terms of the development agreement, Beta Bionics and Senseonics will work together to combine the two systems in the hopes of driving insulin and glucagon dosing […]
Senseonics Q1 misses on EPS
Shares in Senseonics (NYSE:SENS) have fallen slightly today after the continuous glucose monitoring-focused medtech company posted first quarter earnings that missed on earnings per share expectations but beat sales consensus on Wall Street. The Germantown, Md.-based company posted losses of $22.3 million, or 16¢ per share, on sales of $2.9 million for the three months […]
FDA committee backs Senseonics’ implantable continuous glucose monitor
An FDA advisory panel voted unanimously to recommend approval for Senseonics‘ (NYSE:SENS) implantable continuous glucose monitor, Eversense, the company touted this week. The panel of medical experts voted 8-0 that the benefits of the technology outweigh the risks and that the system, which works for up to 90 days, is safe and effective. Get the full […]
- 1
- 2
- 3
- 4
- Next Page »
MassDevice Network
@MassDevice
LinkedIn